← Back to Screener
Establishment Labs Holdings Inc. (ESTA)
Price$74.31
Value ScoreF
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-0.68%
Price vs S&P 500 (4W)3.55%
VGM Score57.34
Market Capitalization$2.19B
All Metrics
Book Value / Share (Quarterly)$0.50
P/TBV (Annual)155.66x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.29%
Cash Flow / Share (Quarterly)$-1.43
Price vs S&P 500 (YTD)-6.20%
Gross Margin (TTM)70.06%
Net Profit Margin (TTM)-19.05%
EPS (TTM)$-1.48
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-1.48
Revenue Growth (5Y)20.04%
EPS (Annual)$-1.72
ROI (Annual)-18.01%
Gross Margin (Annual)69.32%
Net Profit Margin (5Y Avg)-40.32%
Cash / Share (Quarterly)$2.32
Revenue Growth QoQ (YoY)44.71%
ROA (Last FY)-14.30%
Revenue Growth TTM (YoY)34.86%
EBITD / Share (TTM)$-0.64
ROE (5Y Avg)-186.96%
Operating Margin (TTM)-12.45%
Cash Flow / Share (Annual)$-1.97
P/B Ratio147.94x
P/B Ratio (Quarterly)112.86x
Net Income / Employee (Annual)$-50,900
EV / Revenue (TTM)10.36x
Net Interest Coverage (TTM)-2.15x
ROA (TTM)-12.71%
EPS Incl Extra (Annual)$-1.72
Current Ratio (Annual)3.04x
Quick Ratio (Quarterly)1.82x
3-Month Avg Trading Volume0.51M
52-Week Price Return95.45%
Revenue / Employee (TTM)$228,700
Tangible BV / Share (Quarterly)$0.19
P/S Ratio (Annual)10.36x
Asset Turnover (Annual)0.59x
52-Week High$83.31
Operating Margin (5Y Avg)-28.81%
EPS Excl Extra (Annual)$-1.72
CapEx CAGR (5Y)11.44%
Tangible BV CAGR (5Y)-17.78%
26-Week Price Return7.24%
Quick Ratio (Annual)1.91x
13-Week Price Return4.13%
Total Debt / Equity (Annual)11.04x
Current Ratio (Quarterly)2.96x
Enterprise Value$2.38B
Revenue / Share Growth (5Y)14.41%
Asset Turnover (TTM)0.67x
Book Value / Share Growth (5Y)-16.01%
Revenue / Employee (Annual)$210,200
Inventory Turnover (Annual)0.79x
Pretax Margin (Annual)-27.49%
Cash / Share (Annual)$2.58
3-Month Return Std Dev52.92%
Gross Margin (5Y Avg)66.68%
Net Income / Employee (TTM)$-43,600
ROE (Last FY)-216.86%
Net Interest Coverage (Annual)-1.23x
EPS Basic Excl Extra (Annual)$-1.72
Receivables Turnover (TTM)3.27x
Total Debt / Equity (Quarterly)17.58x
EPS Incl Extra (TTM)$-1.48
Receivables Turnover (Annual)2.96x
ROI (TTM)-16.62%
P/S Ratio (TTM)9.53x
Pretax Margin (5Y Avg)-40.48%
Revenue / Share (Annual)$7.13
Tangible BV / Share (Annual)$0.46
Price vs S&P 500 (52W)71.08%
Year-to-Date Return1.96%
5-Day Price Return9.15%
EPS Normalized (Annual)$-1.72
ROA (5Y Avg)-26.60%
Net Profit Margin (Annual)-24.19%
Month-to-Date Return5.12%
Cash Flow / Share (TTM)$-2.69
EBITD / Share (Annual)$-0.99
Operating Margin (Annual)-18.48%
LT Debt / Equity (Annual)10.51x
ROI (5Y Avg)-31.49%
LT Debt / Equity (Quarterly)16.82x
EPS Basic Excl Extra (TTM)$-1.48
P/TBV (Quarterly)304.47x
P/B Ratio (Annual)89.94x
Inventory Turnover (TTM)0.78x
Pretax Margin (TTM)-22.35%
Book Value / Share (Annual)$0.80
Price vs S&P 500 (13W)-4.12%
Beta1.11x
Revenue / Share (TTM)$7.67
ROE (TTM)-225.86%
52-Week Low$33.35
vGradeF
gGradeA
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.45est. -0.35
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.20
4.20
4.20
4.20
Industry Peers — Orthopedic & Prosthetic Devices(33)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ESTAEstablishment Labs Holdings Inc. | F | A | B | $74.31 |
| ISRGIntuitive Surgical Inc. | F | B | C | $422.06 |
| EWEdwards Lifesciences Corp | D | C | C | $85.96 |
| STESTERIS plc | C | B | C | $212.35 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | C | $87.33 |
| ALGNAlign Technology Inc | B | C | C | $167.74 |
| SNNSmith & Nephew plc | B | C | C | $30.61 |
| MSAMine Safety Incorporated | B | C | C | $161.30 |
| ENOVEnovis Corporation | B | D | C | $23.78 |
| CDRECadre Holdings, Inc. | C | C | D | $30.01 |
| AVNSAvanos Medical, Inc. | B | D | A | $25.05 |
About
Establishment Labs Holdings Inc. is a medical technology company specializing in the design, manufacture, and distribution of silicone-filled breast and body-shaping implants under the Motiva brand. The company distributes its aesthetic medical devices through direct sales channels to physicians, hospitals, clinics, and medical distributors across Europe, Latin America, Asia-Pacific, the Middle East, and other regions.